Clinical Trial Update: Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease [Phase 1]

View source ↗

Summary

A Phase I trial of MT-0169 for CD38-positive acute leukemia in relapsed/refractory or measurable residual disease has been withdrawn from ClinicalTrials.gov.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• MT-0169

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 1 | Status: WITHDRAWN